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Background:  Available  studies  vary  in  their  estimated  prevalence  of  attention  deﬁcit/hyperactivity  disor-
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der (ADHD)  in substance  use  disorder  (SUD)  patients,  ranging  from  2 to 83%.  A better  understanding  of
the  possible  reasons  for  this  variability  and  the  effect  of  the  change  from  DSM-IV  to  DSM-5  is  needed.
Methods:  A  two stage  international  multi-center,  cross-sectional  study  in 10 countries,  among  patients
form  inpatient  and  outpatient  addiction  treatment  centers  for  alcohol  and/or  drug  use  disorder  patients.  A
total  of  3558  treatment  seeking  SUD patients  were  screened  for adult  ADHD.  A subsample  of  1276 subjects,
both screen  positive  and  screen  negative  patients,  participated  in a  structured  diagnostic  interview.
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Results:  Prevalence  of DSM-IV  and  DSM-5  adult  ADHD  varied  for DSM-IV  from  5.4% (CI 95%: 2.4–8.3)  for
Hungary  to  31.3%  (CI 95%:25.2–37.5)  for  Norway  and  for DSM-5  from  7.6%  (CI  95%:  4.1–11.1) for  Hungary  to
32.6%  (CI  95%:  26.4–38.8)  for  Norway.  Using  the  same  assessment  procedures  in  all  countries  and  centers
resulted  in  substantial  reduction  of  the  variability  in  the  prevalence  of  adult  ADHD  reported  in  previous
studies  among  SUD  patients  (2–83%  → 5.4–31.3%).  The  remaining  variability  was  partly  explained  by
primary  substance  of  abuse  and  by  country  (Nordic  versus  non-Nordic  countries).  Prevalence  estimates
for  DSM-5  were  slightly  higher  than  for  DSM-IV.
Conclusions: Given  the  generally  high  prevalence  of  adult  ADHD,  all  treatment  seeking  SUD  patients
should be screened  and,  after  a conﬁrmed  diagnosis,  treated  for  ADHD  since  the  literature  indicates  poor
prognoses  of  SUD  in  treatment  seeking  SUD  patients  with  ADHD.
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tion improved. All participants gave signed informed consent after. Introduction
Attention Deﬁcit/Hyperactivity Disorder (ADHD) is one of the
ost common mental health disorders affecting children and ado-
escents (Polanczyk and Rohde, 2007). The prevalence of childhood
DHD in general population surveys varies from 6 to 9% (Kessler
t al., 2005a), whereas for adult ADHD a pooled estimated preva-
ence of 2.5% was reported (Simon et al., 2009). A meta-analysis of
ongitudinal data suggests that in two-thirds of the cases childhood
DHD persists into adulthood (Faraone et al., 2006).
Studies in adults with substance use disorders (SUD) show a
igher prevalence of adult ADHD compared to the general pop-
lation (Rounsaville and Carroll, 1991; Levin et al., 1998; King
t al., 1999; Wilens, 2007; Ohlmeier et al., 2008; Arias et al., 2008;
untley et al., 2012). This is important since research suggests that
o-occurring ADHD and SUD are associated with a more severe
ourse of substance use and poorer treatment outcome (Wilens and
usillo, 2007; Carroll and Rounsaville, 1993). Moreover, patients
ith these co-occurring disorders have higher rates of other psy-
hiatric disorders (Kessler et al., 2005a; Wilens et al., 2005).
Prevalence rates of ADHD in SUD patients show an enor-
ous variation ranging from 2% in substance abusing Icelandic
dolescents (Hannesdottir et al., 2001) to 83% in Japanese metham-
hetamine and inhalant abusers (Matsumoto et al., 2005). In a
ecent meta-analysis by Van Emmerik-van Oortmerssen et al.
2013), reporting on 12 studies in adult treatment seeking SUD
atients, the pooled ADHD prevalence rate was  23.3%, ranging
rom 10.0 to 54.1% in individual studies. Possible explanations
or this huge variability include differences in diagnostic crite-
ia, primary drug of abuse, country speciﬁc factors (treatment
ffer, service structure), treatment setting (e.g., inpatient vs. outpa-
ient treatment), clinical biases and demographic factors. However,
he relative effect of these factors has not been studied, because
he studies so far vary considerably in the deﬁnition of adult
DHD and the diagnostic procedures and assessment instruments.
ence, although there is increasing recognition of the importance
f adult ADHD in treatment seeking SUD subjects, there is con-
iderable uncertainty about the magnitude of the problem in this
opulation, and the factors that affect variability of the preva-
ence.
In addition, changes in criteria for adult ADHD in the newest
dition of the Diagnostic and Statistical Manual of Mental Disorders,
SM-5 (American Psychological Association, 2013) may  affect the
revalence of adult ADHD in SUD patients. First, the increase in
he age threshold for the onset of ADHD symptoms from ‘prior to
he age of 7 years’ to ‘prior to the age of 12 years’, may  increase the
revalence of ADHD. Second, the reduction in the minimum number
f symptoms needed for a diagnosis of adult ADHD from 6 to 5 out of
 symptoms for either inattention and/or hyperactivity/impulsivity
ay  increase the prevalence of adult ADHD. These changes have
een criticized because they may  inﬂate the prevalence of ADHD
ith serious consequences for practice, policy and research (Batstra
nd Frances, 2012; Frances and Widiger, 2012). Nonetheless there 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.
has been no empirical examination of this issue in clinical samples
of SUD patients so far.
The IASP study represents the ﬁrst cross-national study of
ADHD among treatment seeking SUD patients. Data was collected
from participating addiction treatment centers all using the same
diagnostic criteria and conducting the same sampling design and
assessment procedures and instruments. In 10 countries across the
globe, this study examines the effect of changes in the diagnostic
system (DSM-IV vs. DSM-5) and the effects of country, age, gender,
setting (inpatient vs. outpatient) and primary substance of abuse
(alcohol vs. drugs) on the variation in the prevalence of childhood
and adult ADHD in treatment seeking SUD patients.
2. Method
2.1. Design and procedure
Data was collected in the context of the International ADHD
in Substance Use Disorders Prevalence study (IASP), completed
within the framework of the International Collaboration on ADHD
and Substance Abuse (ICASA). The IASP is an international, multi-
center, cross-sectional study consisting of a screening stage and
a full assessment stage. Australia, Belgium, France, Hungary, the
Netherlands, Norway, Spain, Sweden, Switzerland and the United
States participated in the screening stage. France, Hungary, the
Netherlands, Norway, Spain, Sweden, and Switzerland also partic-
ipated in the full assessment stage. For a detailed description of
the methodology (including choice of instruments, translation and
training procedures), study population and screening results the
reader is referred to Van de Glind et al. (2013a). The IASP study is a
large study with many different aspects, and data on other research
topics have been and will be published. For example, results on the
psychometric quality of the Adult ADHD Self-Report Scale (ASRS
V 1.1.; Kessler et al., 2005a) were published in Van de Glind et al.
(2013b) and a paper on the psychiatric comorbidity of SUD patients
with and without ADHD is currently under revision (Van Emmerik-
van Oortmerssen et al., 2013).
2.2. Participants
A random sample of 3558 patients, 18–65 years, seeking
treatment for SUD for a new treatment episode, were asked to par-
ticipate in the study in each participating center/ward. Patients
with insufﬁcient language skills or unwilling to sign informed
consent were excluded from the study. Patients who were intox-
icated or currently suffering from severe physical or mental
problems were asked to join the study when their clinical condi-receiving verbal and written information about the study. They
did not receive ﬁnancial compensation, except for Australia, where
patients received AUD $20 reimbursement for associated costs. The
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tudy was approved by the local Ethical Review Board in each par-
icipating country.
.3. Assessments
In the ﬁrst stage, all participants ﬁlled out a questionnaire
n demographics and substance use. In addition, the ASRS V 1.1
Kessler et al., 2005b) was administered assessing ADHD symptoms
n adulthood (American Psychological Association, 1994). ADHD
ymptoms in the ASRS are rated from “never” to “very often” and
cored from 0 to 4. Items 1–3 are positively endorsed with scores
2, items 4–6 with scores ≥3. The ﬁrst six items have been found
ost predictive of ADHD diagnosis, and were used as a screener
ith a cut off of four positively endorsed items for a positive
creening result.
Three countries (Belgium, Australia, United States of America)
ith 963 subjects participated in the screening stage only. All
atients from the other 7 countries, regardless of their ASRS result,
ere referred to the second stage, resulting in 1276 subjects from
even countries. In this stage, a psychiatric interview was admin-
stered to assess the presence of SUD, ADHD and other commonly
ccurring psychiatric disorders in SUD patients.
For the diagnosis of ADHD, we applied the Conners’ Adult
DHD Diagnostic Interview for DSM-IV (CAADID; Epstein et al.,
001), a valid semi-structured interview. CAADID-Part I was ﬁlled
ut by the patient before the interview, collecting information
n demographics, developmental course, ADHD risk factors, and
sychopathology. CAADID-Part II was administered by trained cli-
icians and is designed to evaluate the presence of DSM-IV ADHD
riteria in childhood and in adulthood, as follows: (A) presence of
ymptoms (six out of nine symptoms of inattention and/or hyper-
ctivity/impulsivity), (B) age of onset before the age of seven, (C)
ervasiveness of the symptoms, (D) impairment caused by the
ymptoms, and (E) the symptoms are not better explained by
nother disorder.
To evaluate Criterion E, further information was collected using
wo additional semi-structured interviews: the Mini International
europsychiatric Interview (M.I.N.I.) Plus version 5.0.0 (Sheehan
t al., 1998) to assess prior and current episodes of mood disorders,
ipolar disorder and antisocial personality disorder (APD); and the
orderline module of the Structured Clinical Interview for DSM-
V personality disorders (SCID II) (Williams et al., 1992) to assess
orderline personality disorder (BPD).
The DSM-IV also includes a code ADHD–Not Otherwise Speciﬁed
ADHD-NOS) for individuals not meeting the age criteria (symp-
oms present before the age of 12 instead of before the age of 7)
nd/or symptom criteria for ADHD but showing ADHD symptoms
≥4 instead of ≥6 out of 9) and who do fulﬁll criteria of perva-
iveness and impairment. In addition, the American Psychiatric
ssociation (APA) presented the main changes in criteria for ADHD
n childhood and adulthood for DSM-5 (APA, 2013).
To assess ADHD diagnosis according to the ADHD-NOS criteria
nd DSM-5 criteria, we adapted the diagnostic algorithm of the
AADID using a different cut off for the age of onset criterion of
12 and different cut offs for the number of symptom criterion of 4
DSM-IV ADHD-NOS) and 5 (DSM-5) respectively.
There is debate on whether or not a retrospectively obtained
iagnosis of childhood ADHD should be mandatory for the diag-
osis of adult ADHD (Faraone and Antshel, 2008). For this paper
e used the CAADID algorithm for the diagnosis of adult ADHD,
ncluding a retrospectively obtained diagnosis of childhood ADHD
eeting all of the 5 criteria. This procedure results in conservative
revalence rates of adult ADHD as it is stricter than the DSM crite-
ia that does not expressly demand meeting full childhood ADHD
riteria.Dependence 134 (2014) 158– 166
SUD was assessed via self-report measures related to the current
primary substance of abuse, and it included only current use of
either alcohol or illicit drugs, assuming that all of those coming for
treatment to an addiction treatment center has a SUD.
For more detailed information on validation of the ASRS and
CAADID, the reader is referred to Van de Glind et al. (2013a,b).
2.4. Statistical analyses
Although all of the participants were referred to the second
stage, the proportion of ASRS positives (40.0%) participating in the
second stage slightly differed from the proportion of ASRS positives
(36.3%) in those who  dropped out after stage one (in those countries
participating in stage 2; Van de Glind et al., 2013a,b). Because
this effect was  different for the different countries, we constructed
weights based on the percentage of ASRS positives, CAADID cases,
and country. To prevent biased standard errors, these weights were
constructed in such a way that the overall number of participants
did not change. All tests, estimates and conﬁdence intervals are
based on weighted data. SPSS 20 was used for analyzing the data.
3. Results
3.1. Preliminary analyses
Of the 2595 patients screened in the seven countries participat-
ing in stage two, 1276 patients completed the CAADID. There were
no signiﬁcant differences between the patients who completed the
CAADID and the drop-outs, with two  exceptions: the mean age in
Norway and Spain was signiﬁcantly higher for participants than for
drop outs, and the above mentioned difference in ASRS score. The
latter was taken into account as described in the methods section.
Of 1276 included subjects with completed CAADID interviews, 511
had a positive score and the remaining 765 had a negative score on
the ASRS.
3.2. Demographics (Table 1)
Table 1 describes the demographic and substance use character-
istics of the 1276 participants. Mean age varied between 37 years
in France to 43 years in Hungary, approximately one in four were
women, fewer than one third were employed, almost one in ten
were homeless and only one in four were currently married or
had a partner. The primary substance of abuse varied considerably
between the countries. Alcohol was the most frequent primary sub-
stance of abuse in the total sample (54.6%), followed by stimulants
(15.1%), cannabis (10.8%), opiates (10.8%) and other drugs (8.6%).
With the exception of housing status, there was  a signiﬁcant coun-
try effect for all demographic and clinical characteristics (p < .001;
adjusted for multiple testing). The number of ASRS positives var-
ied between countries ranging from 20.8% in Hungary to 65.9% in
Norway.
3.3. Ranges of ADHD prevalence rates (Table 2)
Table 2 presents the ranges of weighted prevalence rates of
childhood and adult ADHD according to DSM-IV and DSM-5 and
for adult ADHD-NOS according to DSM-IV. The prevalence of adult
ADHD-DSM-IV differed markedly across countries with Hungary
having the lowest and Norway having the highest rate: 5.4% (CI
95%: 2.4–8.3) and 31.3% (CI 95%: 25.2–37.5), respectively. Based
on DSM-5 criteria the prevalence for adult ADHD were slightly
higher, ranging from 7.6% (CI 95%: 4.1–11.1) in Hungary to 32.6% (CI
95%: 26.4–38.8) in Norway. However the DSM-5 rates were within
the range of rates observed for adult ADHD-NOS (DSM-IV): 8.2%
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Table 1
Main characteristics of the study population (N = 1276).
France
(n = 157)
Hungary
(n = 226)
Netherlands
(n = 129)
Norway
(n = 220)
Spain
(n = 222)
Sweden
(n = 168)
Switzerland
(n = 154)
Total
(N = 1276)
p
Age M (SD) 36.8 (10.6) 43.1 (12.1) 40.4 (10.3) 38.1 (10.7) 37.0 (9.8) 42.6 (11.6) 42.5 (10.8) 40.0 (11.2) F(6, 1265) = 11.55 <.001
ASRS  screen positive
(%)
40.1 20.8 53.5 65.9 35.6 37.5 28.6 40.0 Wald(6) = 89.01 <.001
Female (%) 44 (28.0) 55 (24.3) 23 (17.8) 69 (31.3) 46 (20.7) 52 (31.0) 51 (33.6) 340 (26.7) Wald(6) = 16.64 .010
Employed (%) 51 (32.5) 53 (24.0) 68 (53.1) 55 (26.4) 81 (36.7) 56 (35.9) 20 (13.4) 384 (31.0) Wald(6) = 54.80 <.001
Homeless/shelter (%) 9 (5.7) 27 (13.2) 10 (7.8) 14 (6.9) 19 (8.6) 18 (5.9) 9 (11.0) 106 (8.6) Wald(6) = 11.56 .073
Married/partner (%) 35 (22.3) 71 (31.7) 30 (23.3) 39 (18.4) 58 (26.4) 47 (28.7) 47 (30.9) 327 (25.9) Wald(6) = 14.57 .024
Main  substance
(missing):
0 0 0 6 1 3 2 12
–  Alcohol (%) 79 (50.3) 169 (74.8) 79 (61.2) 68 (31.8) 57 (25.8) 92 (55.8) 146 (96.1) 690 (54.6) Wald(6) = 189.31 <.001
–  Stimulants (%) 10 (6.4) 13 (5.8) 12 (9.3) 57 (26.6) 81 (36.7) 16 (9.7) 2 (1.3) 191 (15.1) Wald(6) = 117.16 <.001
–  Opiates (%) 15 (9.6) 8 (3.5) 1 (0.8) 37 (17.3) 39 (17.6) 35 (21.2) 2 (1.3) 137 (10.8) Wald(6) = 51.79 <.001
–  Cannabis (%) 32 (20.4) 4 (1.8) 31 (24.0) 30 (14.0) 30 (13.6) 10 (6.1) 0 (0.0) 137 (10.8) Wald(6) = 39.25 <.001
–  Other drugs (%) 21 (13.4) 32 (14.2) 6 (4.7) 22 (10.3) 14 (6.3) 12 (7.3) 2 (1.3) 109 (8.6) Wald(6) = 24.77 <.001
Table 2
Prevalence of childhood (retrospective) and adult (current) ADHD and ADHD-NOS according to DSM-IV criteria and to DSM-5 criteria.
France
(n = 157)
Hungary
(n = 226)
Netherlands
(n = 129)
Norway
(n = 220)
Spain
(n = 222)
Sweden
(n = 168)
Switzerland
(n = 154)
Range
(N = 1276)
Childhood ADHD
DSM-IV %
21.3 12. 9 15.0 41.0 10.6 27.7 15.1 10.6–41.0
(CI  95%) (14.9–27.7) (8.6–17.3) (8.9–21.2) (34.5–47-5) (6.5–14.6) (20.9–34.5) (9.4–20.8)
Childhood ADHD
DSM-5
23.2 12.9 15.0 42.3 13.0 29.1 15.6 12.9–42.3
Age  of onset <12% (CI
95%)
(16.6–29.8) (8.6–17.3) (8.9–21.2) (35.7–48.8) (8.5–17.4) (22.2–36.0) (9.8–21.3)
Adult  ADHD DSM-IV 11.2 5.4 10.1 31.3 9.2 19.7 6.1 5.4–31.3
%  (CI 95%)a (6.3–16.2) (2.4–8.3) (4.9–15.3) (25.2–37.5) (5.4–13.0) (13.7–25.7) (2.3–9.9)
Adult  ADHD DSM-5b 16.2 7.6 11.8 32.6 10.6 22.4 7.7 7.6–32.6
Age  of onset <12 and #
symptoms 5/9% (CI
95%)
(10.5–22.0) (4.1–11.1) (6.2–17.3) (26.4–38.8) (6.6–14.7) (16.1–28.7) (3.5–12.0)
Adult  ADHD DSM-IV
ADHD-NOS)b
16.9 8.9 12.3 34.5 10.6 22.4 8.2 8.2–34.5
Combined: age of onset
<12 and # symptoms
4/9% (CI 95%)
(11.0–22.7) (5.2–12.7) (6.7–18.0) (28.2–40.7) (6.6–14.7) (16.1–28.7) (3.9–12.5)
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CI 95%: 3.9–12.5) in Switzerland to 34.5% (CI 95%: 28.2–40.7) in
orway.
The percentage of patients with DSM-IV childhood ADHD also
eeting criteria for DSM-IV adult ADHD (ADHD persistence into
dulthood) varied considerably between countries, ranging from
8% in Hungary to 90% in Spain.
.4. Stratiﬁed analyses: setting and primary substance of abuse
Tables 3 and 4)
We  were unable to statistically control for country, because
ountry was confounded with setting (inpatient vs. outpatient)
nd/or by primary substance of abuse (alcohol vs. drugs) with only
ne country (Norway) including both inpatients and outpatients
nd one country (Switzerland) including almost only patients with
lcohol use disorders (see Table S13). Therefore, we performed
nalyses stratiﬁed by setting and primary substance of abuse (see
able 3). In these results the exact binomial conﬁdence inter-
als were calculated using a method proposed by Morisette and
horram (1998).
Using DSM-IV criteria for adult ADHD based on the CAADID algo-
ithm (including the mandatory presence of full childhood ADHD
3 Supplementary material can be found by accessing the online version of this
aper. Please see Appendix A for more information.DSM-IV criteria for Childhood ADHD.
DSM-5: adjusted age of onset <12 criterion for childhood.
diagnosis), the prevalence is lower among treatment seeking SUD
patients whose primary substance of abuse was  alcohol, compared
to those whose primary substance of abuse was  illicit drugs. Simi-
larly, the prevalence of adult ADHD was lower among outpatients
than among the inpatients.
However, even within these strata, there was a large country
effect, with prevalence rates ranging from 5 to 22% in inpatients
with alcohol use disorders (AUD) and 4 to14% in AUD outpatients.
Among inpatients with dug use disorders (DUD), prevalence rates
ranged from 5 to 52% and, among DUD outpatient, from 10 to 33%.
These large country differences were mainly due to the relatively
high prevalence rates for all subgroups in the Nordic countries
(Norway and Sweden). After adjustment for age, gender, occupa-
tional status, housing and marital status there was  still a large and
statistically signiﬁcant effect of Nordic versus non-Nordic countries
on the prevalence estimates, After post hoc stratiﬁcation on Nordic
versus non-Nordic countries the difference in prevalence of ADHD
within Nordic and within non-Nordic countries was no longer sig-
niﬁcant (see Tables 3 and 4).
4. DiscussionThe present study is, to our knowledge, the ﬁrst multinational
study on the prevalence of ADHD in adult treatment seeking SUD
patients. Based on DSM-IV criteria, the reported rates of adult
ADHD were much higher in our sample of treatment seeking SUD
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Table 3
Prevalence of ADHD (DSM-IV).
Inpatients alcohol (n = 339)a, weighted data Inpatients drugs (n = 109a), weighted data
Childhood DSM-IV Adult ADHD DSM-IV Childhood DSM-IV Adult ADHD DSM-IV
Prevalence 95% cib Prevalence 95% cib Prevalence 95% cib Prevalence 95% cib
Hungary (169a) 12% 7–18 5% 02–10 Hungary (57a) 16% 8–28 5% 1–15
Norway (24a) 43% 23–64 22% 08–44 Norway (52a) 57% 42–71 52% 37–66
Switzerland (146a) 15% 09–21 5% 02–10
–  All countriesf 15% 12–20 6% 4–10 – All countriesf 35% 26–44 27% 19–36
–  Without Nordice 13% 10–17 5% 3–8
–  Only Nordic 43% 23–64 22% 8–44
Observed range Observed range
–  All countries 12–43% 5–22% – All countries 16–57% 5–52%
–  Without Nordic 12–15% 5.1–5.4%
–  Only Nordic n.a.d n.a.d
Effect countryc Effect countryc
– All countries Wald(2); (p) 16.67 (<.001) 8.00 (.018) – All countries
Wald(1); (p)
10.58 (.001) 14.13 (<.001)
–  Without Nordic Wald(1); (p) .024 (.878) .585 (.444)
– Only Nordic n.a.d n.a.d
Inpatients alcohol (n = 339) and inpatients drugs (n = 109), weighted data.
a Presented is the non-weighted n.
b Exact binomial conﬁdence interval using the approach by Morisette and Khorram (1998).
c Effect of country on prevalence adjusted for age, sex, occupational status, housing and marital status.
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Od Not applicable.
e Nordic countries: Norway and Sweden.
f All countries: meaning all countries with subjects in this setting.
atients than in the general population (6–9% childhood ADHD;
.5% adult ADHD; Kessler et al., 2005c; Simon et al., 2009). The
revalence of DSM-IV adult ADHD varied between countries from
.4% (CI 95%: 2.4–8.3) in Hungary to 31.3% (CI 95%: 25.2–37.5)
n Norway. Although this is a broad range of prevalence rates,
he range is much smaller than the ranges reported on ADHD in
UD patients in the literature so far (2–85%; Hannesdottir et al.,
able 4
revalence of ADHD (DSM-IV).
Outpatients alcohol (n = 351a), weighted data
Childhood DSM-IV Adult ADHD DSM-IV 
Prevalence 95% cib Prevalence 95% cib
France (79a) 12% 6–22 6% 2–14 
Netherlands (79a) 14% 7–23 10% 5–19 
Norway (44a) 25% 14–40 14% 6–27 
Spain  (57a) 4% 0.5–13 4% 1–13 
Sweden (92a) 17% 10–27 13% 6–21 
–  All countriesf 14% 11–18 9% 7–13 
–  Without Nordice 11% 7–16 7% 4–12 
–  Only Nordic 20% 14–28 13% 8–20 
Observed range 
–  All countriese 4–25% 4–14% 
–  Without Nordicd 4–12% 4–10% 
–  Only Nordic 17.25% 13–14% 
Effect countryc
– All countries Wald(4); (p) 10.23 (.037) 7.06 (.133) 
–  Without Nordic Wald(2); (p) 4.62 (.099) 2.79 (.248) 
–  Only Nordic Wald(1); (p) .003 (.957) .60 (.440) 
utpatients alcohol (n = 351) and outpatients drugs (n = 454), weighted data.
a Presented is the non-weighted n.
b Exact binomial conﬁdence interval using the approach by Morisette and Khorram (19
c Effect of country on prevalence adjusted for age, sex, occupational status, housing an
d Not applicable.
e Nordic countries: Norway and Sweden.
f All countries: meaning all countries with subjects in this setting.2001; Matsumoto et al., 2005) and the range reported in a recent
meta-analysis in treatment seeking SUD patients (10–54%; Van
Emmerik-van Oortmerssen et al., 2012); a ﬁnding that is probably
related to the fact that in the current study the same classiﬁcation
and the same diagnostic procedures and instruments were used.
Furthermore, post hoc analyses showed that the remaining vari-
ation in prevalence of adult ADHD between the various countries
Outpatients drugs (n = 454a), weighted data
Childhood DSM-IV Adult ADHD DSM-IV
Prevalence 95% cib Prevalence 95% cib
France (78a) 30% 20–42 16% 9–27
Netherlands
(50a)
17% 7–32 10% 3–22
Norway (89a) 41% 30–52 33% 23–43
Spain (164a) 12% 8–19 11% 7–17
Sweden (73a) 37% 26–49 26% 16–37
– All countriesf 26% 21–30 18% 15–22
– Without
Nordice
14% 14–23 12% 9–17
– Only Nordic 39% 32–47 29% 22–37
Observed range
– All countriesf 12–41% 10–33%
– Without
Nordice
12–30% 10–16%
– Only Nordic 37–41% 26–33%
Effect countryc
– All countries
Wald(4); (p)
30.54 (<.001) 18.47 (.001)
– Without
Nordic
Wald(2); (p)
9.33 (.009) 1.60 (.449)
– Only Nordic
Wald(1); (p)
.15 (.699) .016 (.889)
98)30.
d marital status.
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as mainly caused by the high prevalence in the Nordic countries
Norway and Sweden). Moreover, these differences between the
ordic and non-Nordic countries were independent of gender, age,
ccupational status, housing and marital status. One explanation
ay  be latitude which may  affect circadian rhythm (Suren et al.,
012) and circadian rhythm may  be related to the incidence and
revalence of ADHD (Friborg et al., 2012). An important indica-
ion for such an inﬂuence of region related to solar intensity on
he prevalence of ADHD has recently been reported (Arns et al.,
013), indicating high solar intensity as a protective factor, possibly
ia improving circadian clock disturbances. However, the preva-
ence rates of childhood ADHD in Scandinavian countries lye well
ithin the range as found in other countries as reported by Faraone
t al. (2003). In Sweden two independent studies found child-
ood ADHD prevalence of 4.0% (Landgren et al., 1996) and 3.7%
Kadesjö and Gillberg, 2001) using DSM-III-R resp. DSM-IV. A Nor-
egian study recently reported childhood ADHD prevalence of 5.2%
Ullebø et al., 2012). Thus, other explanations are likely to be of
ore importance. These other explanations may  be found in coun-
ry speciﬁc reasons, leading to more or less subjects with ADHD
ithin addiction treatment centers, e.g., differences in the public
wareness of ADHD frequently coexisting with SUD resulting in dif-
erences in recognition and referral, and differences in treatment
vailability and treatment approach for patients with co-occurring
DHD and SUD. Unfortunately, no data is currently available to sup-
ort these explanations. Moreover, selection of treatment centers
ithin the various countries was not random and thus the observed
ifferences in prevalence may  also be a result of selection bias at
he center level. However, all participating centers indicated that
heir center was representative for the national situation. More-
ver, national non-representativeness does not directly explain the
ordic vs. non-Nordic gradient and it is thus rejected as a plausible
xplanation.
The observed range of adult ADHD prevalence rates among inpa-
ients (AUD: 5–22%; DUD: 5–52%) is difﬁcult to interpret as these
eﬂect participating sites from 3 countries with inpatient AUD sites
nd 2 countries with inpatient DUD sites only (see Table 3). The
UD outpatient adult ADHD prevalence rates ranged from 4 to
4% and the DUD outpatient adult ADHD prevalence rates ranged
rom 10 to 33%. These results show that ADHD is more prevalent
n patients with illicit drug use than in patients with alcohol use
s their primary addiction. This is consistent with the ﬁnding that
DHD and DUDs are familially/genetically related, whereas ADHD
nd AUDs are not (Biederman et al., 2008). However, this ﬁnding
s inconsistent with the meta-regression analysis of Van Emmerik-
an Oortmerssen et al. (2012) reporting a lower prevalence of adult
DHD in treatment seeking cocaine dependent patients compared
o treatment seeking alcohol and opioid dependent patients.
Although it is possible to calculate overall prevalence rates for
DHD for the total sample, we resisted this temptation. In pre-
enting overall rates we would overrule the important ﬁnding of
he large variability in prevalence rates due to Nordic-non-Nordic
ountry effects, primary substance of abuse and probably other
nknown factors inﬂuencing referral and access of subjects with
dult ADHD and SUD to addiction treatment centers.
The use of DSM-5 criteria resulted in a modest increase in preva-
ence rates: 7.6% (CI 95%: 4.1–11.1) in Hungary to 32.6% (CI 95%:
6.4–38.8) in Norway. The observed DSM-5 prevalence rates were
ll within the rates based on ADHD-NOS criteria in DSM-IV, indi-
ating that DSM-5 may  reduce the use of the NOS category without
ncreasing the prevalence of clinical relevant ADHD syndromes in
reatment seeking SUD patients. Therefore the fear that DSM-5
ould inﬂate the prevalence of ADHD (Batstra and Frances, 2012)
eems not justiﬁed and the change from DSM-IV to DSM-5 will
ave, if any, minimal implications for clinical practice in addiction
reatment centers.Dependence 134 (2014) 158– 166 163
4.1. Limitations
Although our study included a large sample based on a simi-
lar recruitment strategy and assessed with identical instruments
for the diagnosis of adult ADHD, there are several limitations to
consider.
Because of the lack of information about the initial number
of referred patients and the dropout rates in some countries, it
remains unclear to what extent the current sample is represen-
tative of all service attendees, let alone all people affected by a SUD
in the various countries. Although the participants dropping out
from the full assessment stage of the study were very similar to
those who  participated (Van de Glind et al., 2013a,b), the possibil-
ity that there were ADHD related differences that could have biased
the estimates of ADHD cannot be fully discounted. In addition,
requiring sustained abstinence as a criterion for inclusion might
have resulted in more reliable information, but would have poten-
tially excluded some of the more severely dependent participants,
thereby leading to a possible underestimation of the prevalence of
ADHD (Wilens, 2004).
The diagnostic accuracy of adult ADHD can be enhanced by
obtaining additional information from parents or other individ-
uals who knew the patient well during childhood. In this study,
patients were approximately 40 years old and often came from
dissolved families; hence it would be difﬁcult if not impossible
to track down parents or other key informants. When requiring
attainment of collateral information to include SUD patients for
this study, many would have been excluded. This decision how-
ever may  have lowered (Barkley et al., 2002) the prevalence rates
based on the CAADID.
Furthermore, we  obtained information on the primary sub-
stance of abuse via self-report measures during the screening
procedure (stage one), and it included only current use of either
alcohol or illicit drugs. This is a simpliﬁcation of reality, as many
patients use multiple substances and no clear distinction between
primary and non-primary substance of abuse can be made. It is
unclear how this may  have had a speciﬁc impact on the prevalence
rates.
In addition, we have no measures of severity of SUD in our sam-
ple. Since severity of substance use may  be related to treatment
type with inpatients using more substances, this in turn may  have
an effect on the prevalence rates.
Finally, we had limited data on the reliability of the interviews
in the various study locations (Polanczyk and Rohde, 2007). This
may  have inﬂuenced the prevalence rates in some of the countries.
However, all sites were trained in the use of the MINI and the CAA-
DID by the same clinical researcher (GvdG) and all interviewers at
all sites were extensively trained using the same training manual
for all assessment instruments.
4.2. Conclusions
Using the same deﬁnitions and diagnostic instruments in all
countries and centers resulted in substantial reduction of the vari-
ability in the prevalence of adult ADHD reported in previous studies
among SUD patients (2–83%) and treatment seeking SUD  patients
(10.0–54.1%) to 5.4–31.3%. The remaining variability was partly
explained by primary substance of abuse and country. Prevalence
estimates for DSM-5 were slightly higher than for DSM-IV and all
within the rates based on ADHD-NOS criteria in DSM-IV. Therefore,
the change from DSM-IV to DSM-5 will hardly have any effect on the
clinical practice in addiction treatment centers. However, given the
generally high prevalence of adult ADHD in treatment seeking SUD
patients and given the fact that efﬁcacious pharmacologic (Faraone
and Glatt, 2010) and cognitive behavioral (Safren, 2006) interven-
tions exist for the treatment of adult ADHD and its potential impact
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pon the outcomes of SUD treatment, all treatment seeking SUD
atients should be screened and, after conﬁrmed diagnosis, treated
or ADHD since the current literature indicates poor prognoses of
UD in treatment seeking SUD patients with ADHD (Wilens, 2004).
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